REVIEW ON MULTIPLE CHEMICAL SENSITIVITY TO BE PUBLISHED IN " GENERAL AND APPLIED TOXICOLOGY "
Christiane Tourtet B.A.
June 13, 2009
Dr. Martin L Pall, PhD, Professor Emeritus of Biochemistry and Basic Medical Sciences, Washington State University (WA) and Research Director, The Tenth Paradigm Research Group, is absolutely delighted to have been asked by three editors of the prestigious future publication "General Applied Toxicology, 3rd edition", (John Wiley and Sons) to write a review on Multiple Chemical Sensitivity (MCS).
As of now, usually, toxicologists had largely ignored Multiple Chemical Sensitivity (MCS). and it is a great honor for Dr. Martin L. Pall , to have been asked to write a paper on MCS, by three quite prominent scientists , who all have extensively researched and published the actions of chemicals implicated in Multiple Chemical Sensitivity (MCS). This is not only an important recognition of the work of Dr. Martin L. Pall, but also the recognition of Multiple Chemical Sensitivity (MCS ) as a toxicological phenomenon.
The MCS review entitled "Multiple Chemical Sensitivity : Toxicological Questions and Mechanisms" will be a 54 pages chapter in the multivolume set, and will be a most extensively documented publication on Multiple Chemical Sensitivity (MCS). The majority of Dr. Martin L. Pall´s paper
will come from his earlier publications on Multiple Chemical Sensitivity (MCS), however it will also have quite important new sections.
According to Dr. Martin L. Pall, there are seven classes of chemicals that are implicated in Multiple Chemical Sensitivity (MCS), and these seven classes of chemicals can produce indirectly a common response in the body, and that is, increased NMDA activity .As a matter of fact, animal studies have shown that the toxic responses of the members of all seven classes of chemicals, can be lowered by using NMDA antagonist.
So, this not only clearly demonstrates that they produce such an increased activity, but that these increases play a quite important role in producing toxic responses to the chemicals.
Given the fact, that previously, they were six types of evidence implicating an excess of NMDA activity, now there is the compelling evidence that this common response plays a key role in Multiple Chemical Sensitivity (MCS).
Four genetic studies have confirmed the role of these chemicals acting as toxicants in Multiple Chemical Sensitivity (MCS) (only three genetic studies were available at the time the review was written by Dr. Martin L.Pall) and
these studies show that the susceptibility to Multiple Chemical Sensitivity (MCS) is influenced by the genes that determine the metabolism of these chemicals.
These studies implicate six genes in the determination of susceptibility to MCS, and all of them have roles in the metabolism of the chemicals implicated in the onset of cases of MCS. The roles of chemicals in initiating Multiple Chemical Sensitivity (MCS) are thus undeniable.
Dr. Martin L.Pall also points out to the fact, that there have been series of published studies, showing objectively among cases of Multiple Chemical Sensitivity, (MCS) measurable responses to low level exposures, that are distinct from non-MCS cases. Dr. Martin L.Pall , advises that at least three of these studies should be practical specific biomarker tests, that could be applied to clinical settings, and that all these studies are consistent with the mechanism of the NO/ONOO- cycle, as it is thought to play out in Multiple Chemical Sensitivity (MCS) and all provide, indeed, evidence supporting this mechanism.
Dr Martin L.Pall , emphasizes the great need for such specific biomarker tests for Multiple Chemical Sensitivity (MCS), and that these approaches and others for developing these tests should be further studied and he also feels that they may provide in the near future recognized specific biomarkers tests.
All, at the exception of one of the elements of the NO/ONOO-cycle as it is believed to play out in Multiple Chemical Sensitivity (MCS), have been studied in animal models, and all the elements that have been studied, are involved in these animal models. Based on animal model studies alone,
one can truly make a strong case of the NO/ONOO- cycle mechanism.
At the end of his paper, Dr. Martin L. Pall, mentions a list of five areas of future research, which in his judgment, are in most need of further study.
It is important to note the following statement from Dr. Martin L. Pall:
" We do have observational evidence that a protocol based on down – regulating the NO/ONOO- cycle mechanism, is helpful in the treatment of most cases of MCS as well as most cases of ME/CFS and most cases of fibromyalgia. However. at this point, this treatment fails to produce any substantial number of cures and seems to be quite variable in the extent of improvements apparently produced by it. Nevertheless, this approach does produce substantial apparent improvements in many people who have been ill for one, two or more decades. It is my hope that we will be able to add a second phase to such treatment that may start to produce at least some such cures, but that is a hope at this point".
Resource:
Dr. Martin L.Pall, PhD, Professor Emeritus of Biochemistry and Basic Medical Sciences, Letter of Saturday, June 06, 2009.
© 2009 Christiane Tourtet .
As of now, usually, toxicologists had largely ignored Multiple Chemical Sensitivity (MCS). and it is a great honor for Dr. Martin L. Pall , to have been asked to write a paper on MCS, by three quite prominent scientists , who all have extensively researched and published the actions of chemicals implicated in Multiple Chemical Sensitivity (MCS). This is not only an important recognition of the work of Dr. Martin L. Pall, but also the recognition of Multiple Chemical Sensitivity (MCS ) as a toxicological phenomenon.
The MCS review entitled "Multiple Chemical Sensitivity : Toxicological Questions and Mechanisms" will be a 54 pages chapter in the multivolume set, and will be a most extensively documented publication on Multiple Chemical Sensitivity (MCS). The majority of Dr. Martin L. Pall´s paper
will come from his earlier publications on Multiple Chemical Sensitivity (MCS), however it will also have quite important new sections.
According to Dr. Martin L. Pall, there are seven classes of chemicals that are implicated in Multiple Chemical Sensitivity (MCS), and these seven classes of chemicals can produce indirectly a common response in the body, and that is, increased NMDA activity .As a matter of fact, animal studies have shown that the toxic responses of the members of all seven classes of chemicals, can be lowered by using NMDA antagonist.
So, this not only clearly demonstrates that they produce such an increased activity, but that these increases play a quite important role in producing toxic responses to the chemicals.
Given the fact, that previously, they were six types of evidence implicating an excess of NMDA activity, now there is the compelling evidence that this common response plays a key role in Multiple Chemical Sensitivity (MCS).
Four genetic studies have confirmed the role of these chemicals acting as toxicants in Multiple Chemical Sensitivity (MCS) (only three genetic studies were available at the time the review was written by Dr. Martin L.Pall) and
these studies show that the susceptibility to Multiple Chemical Sensitivity (MCS) is influenced by the genes that determine the metabolism of these chemicals.
These studies implicate six genes in the determination of susceptibility to MCS, and all of them have roles in the metabolism of the chemicals implicated in the onset of cases of MCS. The roles of chemicals in initiating Multiple Chemical Sensitivity (MCS) are thus undeniable.
Dr. Martin L.Pall also points out to the fact, that there have been series of published studies, showing objectively among cases of Multiple Chemical Sensitivity, (MCS) measurable responses to low level exposures, that are distinct from non-MCS cases. Dr. Martin L.Pall , advises that at least three of these studies should be practical specific biomarker tests, that could be applied to clinical settings, and that all these studies are consistent with the mechanism of the NO/ONOO- cycle, as it is thought to play out in Multiple Chemical Sensitivity (MCS) and all provide, indeed, evidence supporting this mechanism.
Dr Martin L.Pall , emphasizes the great need for such specific biomarker tests for Multiple Chemical Sensitivity (MCS), and that these approaches and others for developing these tests should be further studied and he also feels that they may provide in the near future recognized specific biomarkers tests.
All, at the exception of one of the elements of the NO/ONOO-cycle as it is believed to play out in Multiple Chemical Sensitivity (MCS), have been studied in animal models, and all the elements that have been studied, are involved in these animal models. Based on animal model studies alone,
one can truly make a strong case of the NO/ONOO- cycle mechanism.
At the end of his paper, Dr. Martin L. Pall, mentions a list of five areas of future research, which in his judgment, are in most need of further study.
It is important to note the following statement from Dr. Martin L. Pall:
" We do have observational evidence that a protocol based on down – regulating the NO/ONOO- cycle mechanism, is helpful in the treatment of most cases of MCS as well as most cases of ME/CFS and most cases of fibromyalgia. However. at this point, this treatment fails to produce any substantial number of cures and seems to be quite variable in the extent of improvements apparently produced by it. Nevertheless, this approach does produce substantial apparent improvements in many people who have been ill for one, two or more decades. It is my hope that we will be able to add a second phase to such treatment that may start to produce at least some such cures, but that is a hope at this point".
Resource:
Dr. Martin L.Pall, PhD, Professor Emeritus of Biochemistry and Basic Medical Sciences, Letter of Saturday, June 06, 2009.
© 2009 Christiane Tourtet .
Print
Email
